Traws Pharma, Inc. (TRAW) Fair Value 2026

TRAW · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.4 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-27, Traws Pharma, Inc. (TRAW) trades at $0.59, versus a $2.53 median fair value across its 2 active models — 331.7% above the current price. QOC: 6.4/10. Value Trap Risk: 32/100 (LOW). 2/13 models active. Within that set, the Bayesian DCF component alone returns $2.43.

Key Facts

Ticker
TRAW
Price
$0.59
Quality Score
6.4/10
Value Trap Risk
32/100
Models Active
2/13
Last Updated
Strength: Regime Cross-Sectional suggests +348.5% upside with 20% confidence
Risk: Limited model coverage (2/13) may reduce confidence

Is Traws Pharma, Inc. (TRAW) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Traws Pharma, Inc. (TRAW) appears undervalued as of : the median of 2 independent fair value estimates is $2.53, 331.7% above the current price of $0.59. Estimates range from $2.43 to $2.63. TRAW scores 6.4/10 on fundamental quality and 32/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. TRAW’s +331.7% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Traws Pharma, Inc. Stock in 2026? →

What Fair Value Does Each Model Give TRAW?

2 Intrinsic Value Models vs. Current Price ($0.59)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $2.43 +314.9%
Relative · Low Conviction
 $2.63 +348.5%

All Models Active

All 2 models are displayed above.

What Is Traws Pharma, Inc. (TRAW) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Traws Pharma, Inc.. Trading at $0.59 against an estimated intrinsic value of $2.53, 2 of 2 active models flag meaningful upside of +331.7% at the median. The most optimistic model, Regime Cross, places fair value at $2.63 (+348.5%), while Bayesian DCF — the most conservative — estimates $2.43 (+314.9%). This +33.6% gap reflects genuine analytical uncertainty about Traws Pharma, Inc.'s intrinsic worth.

What Do the Models Say About TRAW?

2 of 13 models are currently active for TRAW. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for TRAW is $2.53 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $2.43 on its own, implying +314.9% upside from the current price. See which stocks rank higher →

How Does TRAW Rank in Biotechnology?

Among 620 Biotechnology stocks, TRAW ranks #101 by Quality of Company score. CirclFi's QOC score of 6.4/10 evaluates 32 fundamental signals. A score of 6.4 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Traws Pharma, Inc.'s positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including breakthrough therapy designations — shape both the opportunity set and risk profile.

Is TRAW a Value Trap?

CirclFi's Value Trap algorithm assigns TRAW a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Traws Pharma, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Traws Pharma, Inc. earns a quality score of 6.4/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +33.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TRAW valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TRAW's 2 active models, average confidence is 17%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Traws Pharma, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

PTGXProtagonist Therapeutics, Inc.QOC 6.4XNCRXencor, Inc.QOC 6.4RAREUltragenyx Pharmaceutical Inc.QOC 6.4BBIOBridgeBio Pharma, Inc.QOC 6.4KYMRKymera Therapeutics, Inc.QOC 6.5MNOVMediciNova, Inc.QOC 6.4MAZEMaze Therapeutics, Inc.QOC 5.2CNTXContext Therapeutics Inc.QOC 4.6LNAILunai Bioworks Inc.QOC 3.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: PTGX · XNCR · RARE · BBIO · KYMR · MNOV · MAZE · CNTX · LNAI · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to TRAW?

5 companies across all industries closest to TRAW’s Quality of Company score of 6.4/10.

BHRBraemar Hotels & Resorts Inc.QOC 6.4LCUTLifetime Brands, Inc.QOC 6.4WGSGeneDx Holdings Corp.QOC 6.4GSBDGoldman Sachs BDC, Inc.QOC 6.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BHR · LCUT · WGS · GSBD · NVDA

Where Does TRAW Sit in CirclFi's Biotechnology Rankings?

TRAW is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Traws Pharma, Inc.’s Valuation?

What is Traws Pharma, Inc.'s intrinsic value in 2026?

CirclFi puts Traws Pharma, Inc. (TRAW)'s intrinsic value at $2.53 — the median of 2 independent model estimates as of 2026-08-27, ranging from $2.43 to $2.63. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $2.43 on its own. The Quality of Company score is 6.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TRAW overvalued or undervalued right now?

At $0.59, 2 of 2 active models suggest TRAW may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $2.53, 331.7% above the current price of $0.59 — a consensus view that TRAW is undervalued. The assessment depends on which methodology best fits Traws Pharma, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.4 mean for TRAW?

Traws Pharma, Inc.'s QOC of 6.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on TRAW?

CirclFi analyzes TRAW with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is TRAW a value trap in 2026?

Traws Pharma, Inc.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Traws Pharma, Inc. (TRAW) has a median fair value of $2.53 — 331.7% above the current price of $0.59 — as of 2026-08-27.” Source: circlfi.com/stock/TRAW/ · Methodology
Primary sources for this TRAW valuation
  • Financial statements: Traws Pharma, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001130598) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TRAW as of ; valuations recomputed .